Rathbones Group PLC Raises Holdings in ASP Isotopes Inc. $ASPI

Rathbones Group PLC grew its position in shares of ASP Isotopes Inc. (NASDAQ:ASPI) by 68.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 399,599 shares of the company’s stock after purchasing an additional 162,535 shares during the quarter. Rathbones Group PLC owned approximately 0.36% of ASP Isotopes worth $2,138,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in ASPI. Quantbot Technologies LP purchased a new position in shares of ASP Isotopes during the third quarter worth about $34,000. BNP Paribas Financial Markets grew its holdings in shares of ASP Isotopes by 84.9% during the second quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock worth $41,000 after buying an additional 2,548 shares during the last quarter. Close Asset Management Ltd purchased a new position in shares of ASP Isotopes during the third quarter worth about $72,000. Tower Research Capital LLC TRC grew its holdings in shares of ASP Isotopes by 96.7% during the second quarter. Tower Research Capital LLC TRC now owns 10,890 shares of the company’s stock worth $80,000 after buying an additional 5,353 shares during the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of ASP Isotopes by 30.4% during the third quarter. Legal & General Group Plc now owns 8,377 shares of the company’s stock worth $81,000 after buying an additional 1,953 shares during the last quarter. Hedge funds and other institutional investors own 16.80% of the company’s stock.

Insider Activity

In related news, COO Robert Ainscow sold 8,438 shares of the firm’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $5.44, for a total transaction of $45,902.72. Following the transaction, the chief operating officer owned 1,537,817 shares of the company’s stock, valued at $8,365,724.48. This trade represents a 0.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 14.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $13.00.

ASP Isotopes Stock Performance

NASDAQ ASPI opened at $4.07 on Wednesday. The company has a quick ratio of 6.10, a current ratio of 6.14 and a debt-to-equity ratio of 1.04. ASP Isotopes Inc. has a 52-week low of $3.92 and a 52-week high of $14.49. The business’s 50-day moving average price is $5.29 and its 200 day moving average price is $7.01. The firm has a market cap of $451.12 million, a P/E ratio of -3.13 and a beta of 3.59.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.